Company: SHPH
Filing Date: 2025-01-28
Form Type: 8-K
Source: 0001493152-25-003985
Chunk: 0

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-01-28
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item
1.01 Entry into a Material Definitive Agreement.

As
previously disclosed, Shuttle Pharmaceuticals, Inc. (“ Shuttle Pharma”), a wholly owned subsidiary of Shuttle Pharmaceuticals
Holdings, Inc. (the “ Company”), entered into a work order (the “ Work Order”) with Theradex Systems, Inc., a New
Jersey contract research organization (“ CRO”), for purposes of supporting Shuttle Pharma’s “ Phase 2 Study of
Ropidoxuridine as a Radiation Sensitizing Agent During Radiotherapy in Patients with Newly Diagnosed IDH-Wildtype Glioblastoma with Unmethylated
MGMT Promotor.” On January 23, 2025, Shuttle Pharma entered into a change order to the Work Order (the “ Change Order”)
effective as of February 1, 2025. Pursuant to the Change Order, the key changes include, among others, increasing the number of patients
in Phase 2 from 15 to 16, due to inclusion of a replacement patient, increasing the number of sites in “ Phase 2 - Start up”
from four to six, and adding one more investigator site and safety teleconference per activity to allow for medical monitor review of
safety data prior to the teleconference. Additionally, the Change Order includes several small increases in budget due to an increase
in the number of sites within “ Phase 2 - Start up” phase from four to six and a small increase in pass-through costs
due to an increase in travel costs relating to additional site monitoring regulatory visits associated with the increased number of sites.

The
foregoing description of the Change Order does not purport to be complete and is qualified in its entirety by reference to the full text
of such agreement, the form of which is filed herewith as Exhibit 10.1 and is incorporated by reference herein.

Item
9.01. Financial Statements and Exhibits.

(d)
Exhibits.

  Exhibit      Description                                                                                              
      No.                                                                                                               
     10.1      Change Order, dated January 23, 2025, between Shuttle Pharmaceuticals, Inc. and Theradex Systems, Inc.*  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
      104      Cover                                                                                                    

*Certain
portions of this exhibit have been redacted because it (i) is not material and (ii) is the type of information that the company normally
treats as private